Discoid lupus erythematosus (DLE) is a chronic autoimmune skin condition that causes round, coin-shaped lesions, typically on the face, scalp, and ears. It is the most common form of chronic cutaneous lupus, meaning it primarily affects the skin rather than internal organs. Unlike systemic lupus (SLE), which can damage joints, kidneys, and other organs, DLE is usually limited to the skin, though roughly 25% of adult cases eventually progress to systemic disease.
What Causes DLE
DLE develops when the immune system loses its normal tolerance and begins attacking healthy skin cells. This triggers an inflammatory cascade involving immune cells, signaling proteins, and antibodies directed against the body’s own tissue. The specific immune response in DLE is driven primarily by a type of helper immune cell called Th1, which distinguishes it from systemic lupus at a cellular level.
The causes are multifactorial. Genetics play a role, but environmental triggers are often what sets things off. Ultraviolet radiation from sunlight is the single most common trigger. Both UVA and UVB rays penetrate the skin and activate inflammatory pathways that lead to lesion formation. Other known triggers include cigarette smoking, certain medications (particularly some antibiotics that increase sun sensitivity), and possibly viral infections. For many people with DLE, flares follow a predictable pattern tied to sun exposure or one of these environmental factors.
What the Lesions Look and Feel Like
DLE lesions are distinctive. They appear as round, coin-shaped plaques that are often scaly, thick, and red. The most common locations are the scalp, ears, and face, though they can appear elsewhere on the body. Early lesions tend to be red and inflamed, while older ones may develop a lighter or darker discoloration as the skin heals. Over time, the center of a lesion can become thin and scarred while the edges remain raised and active.
One characteristic feature is what happens when you peel off a scale from a DLE lesion: the underside often shows small, spike-like projections that resemble carpet tacks, a finding dermatologists call the “carpet tack sign.” This helps distinguish DLE from other skin conditions that produce similar-looking plaques.
Scarring and Hair Loss
DLE on the scalp is particularly concerning because it can cause permanent hair loss. The inflammation targets the area around hair follicles at the level where the hair’s regenerative stem cells live. In advanced cases, these follicles and the oil glands around them are completely destroyed, leaving behind scar tissue. Once that destruction happens, the hair loss is irreversible under most circumstances.
This is why early treatment matters so much. If DLE on the scalp is caught before significant scarring occurs, the inflammation can be controlled and hair can be preserved. Some newer topical treatments have shown promise in regrowing hair even in scarred areas, but results vary and the window for effective treatment narrows as scarring progresses.
Who Gets DLE
DLE affects women more than men, with studies reporting female-to-male ratios ranging from about 2:1 to as high as 9:1. It occurs across all racial and ethnic groups but disproportionately affects Black and Hispanic populations. Data from the Georgia Lupus Registry found the highest rates in Black women, at roughly 7 to 8 cases per 100,000 people per year. A Manhattan-based registry found prevalence among non-Latino Black populations was about three times higher than among Latino populations and substantially higher than in white populations.
Black patients also tend to develop the condition at a younger age and present with greater initial skin damage. Research from New Zealand found that Maori and Pacific Islander populations had nearly six times the relative risk of DLE compared to people of European descent. These disparities likely reflect a combination of genetic susceptibility and differences in access to early dermatologic care.
Connection to Systemic Lupus
One of the biggest concerns for people diagnosed with DLE is whether it will progress to systemic lupus erythematosus, the form that affects internal organs. A systematic review found that about 25% of adults with DLE eventually develop SLE. In children, the rate is even higher, around 30%. This means the majority of people with DLE will not develop systemic disease, but the risk is significant enough that ongoing monitoring is important.
Signs that DLE may be progressing include joint pain, fatigue, mouth sores, and sensitivity to cold that causes fingers to turn white or blue. Blood tests can also detect certain antibodies that suggest systemic involvement is developing. Regular follow-up with a dermatologist or rheumatologist helps catch these changes early.
How DLE Is Diagnosed
Diagnosis typically involves a combination of physical examination and a skin biopsy. DLE can look similar to other conditions, particularly plaque psoriasis (which produces red, scaly plaques with silvery scales) and cutaneous sarcoidosis (which can mimic many skin conditions and is sometimes called dermatology’s “great imitator”). A biopsy allows a pathologist to examine the pattern of inflammation, the specific immune cells involved, and changes at the junction between the outer and deeper skin layers, all of which help confirm DLE and rule out lookalikes.
Treatment and Management
The first line of treatment for DLE is usually prescription-strength topical anti-inflammatory creams applied directly to the lesions. These help reduce the immune response in the skin and control active flares. For lesions that don’t respond to topical treatment, or for widespread disease, an antimalarial medication called hydroxychloroquine is the standard systemic option. It is well-tolerated, inexpensive, and has been shown to control disease activity and prevent flares. Current guidelines recommend a dose of no more than 5 mg per kilogram of body weight per day to minimize the risk of a rare side effect involving the retina of the eye. For people on hydroxychloroquine, regular eye exams are part of the treatment plan.
In more resistant cases, immunosuppressant medications or steroid injections directly into stubborn lesions may be used. Higher blood levels of hydroxychloroquine have been associated with better protection against flares, so consistent daily use matters more than intermittent treatment during active outbreaks.
Sun Protection and Trigger Avoidance
Because ultraviolet radiation is the most reliable trigger for DLE flares, sun protection is not optional for people with this condition. Dermatologists recommend broad-spectrum sunscreen rated SPF 50 or higher, applied daily regardless of weather. Protective clothing, including long sleeves, wide-brimmed hats, and gloves when practical, adds another layer of defense. Avoiding direct sun exposure between 10 AM and 4 PM, when UV intensity peaks, can significantly reduce flare frequency.
Certain medications can also increase photosensitivity, making the skin more reactive to sunlight. If you have DLE, it’s worth reviewing any current or new prescriptions for this side effect. Quitting smoking is also strongly recommended, as cigarette smoking is a known trigger and may reduce the effectiveness of hydroxychloroquine.